FTO and obesity due to melanocortin 4 receptor deficiency: Pharmacological inhibition of the fat mass and obesity-associated FTO protein is emerging as a promising strategy to develop a therapeutic treatment for obesity and cancer (8, 9, 10, 11, 12, 13), and several inhibitors of the enzyme have been described in the literature (15, 20, 21, 39, 40, 41, 42, 43, 44, 45, 46).